Research at the Paul-Ehrlich-Institut: Findings on Natural Anticoagulants in Treatment of COVID-19
New Findings on the Influence of the Cell Entry Mechanism of SARS-CoV-2 Viruses on the Infection Outcome
Booster Vaccination against COVID-19: Adaptation of Booster Vaccines against Omicron Variants Important for COVID-19 Protection
Antibody Response to Omicron and Other Virus Variants Effectively Replenished after 3rd and 4th COVID-19 Vaccination
Vaccination of Recovered Patients Activates the Immune System against SARS Coronaviruses, but not against common Cold Coronaviruses
Antibodies Post-SARS-CoV-2 Infection – New Insights into the Sensitivity and Detection Duration of Antibody Tests
Antibodies from COVID-19-Vaccinated Individuals Recognise Different Spike Protein Structures than Antibodies from SARS-CoV-2-Infected Individuals
Antibody Formation after Vaccination with Different mRNA Vaccines and after COVID-19 Infection
Heterogeneous Design of Studies Hampers Demonstration of Potential Efficacy of Convalescent Plasma as a COVID-19 Therapeutic Agent
Innate Immune System is Barely the Driver of Excessive Immune Reactions in COVID-19
New Vaccine Platform: 'Two-one replicon-and-VLP-minispike Vaccine' against COVID-19
Measure What Fuses – Tissue Damage through Cell Fusion in COVID-19 and the Role of the Spike Protein
COVID-19 Therapy with Convalescent Plasma – Tests for the Identification of Suitable Donor Plasma
Measles Virus Vaccination-based-SARS-CoV-2 Vaccine induces Immune Response in Mice and Hamsters
COVID-19: How is Severity of the Disease Related to Antibody Response?
More Flexible than Expected - New Findings on the Spike Protein of SARS-CoV-2
3D Mapping of Viruses by Electron Microscopy
SARS-CoV-2 Immunogenity at the Crossroads
Please note: Authors from the Paul-Ehrlich-Institut are highlighted in bold. For online abstracts or full text publications, please follow the links.
Bagato O, Balkema-Buschmann A, Todt D, Weber S, Gömer A, Qu B, Miskey C, Ivics Z, Mettenleiter TC, Finke S, Brown RJP, Breithaupt A, Ushakov DS (2024): Spatiotemporal analysis of SARS-CoV-2 infection reveals an expansive wave of monocyte-derived macrophages associated with vascular damage and virus clearance in hamster lungs.
Microbiol Spectr 12: e02469-23.
Text
Barth I, Weißer K, Gaston-Tischberger D, Mahler V, Keller-Stanislawski B (2023): Anaphylactic reactions after COVID-19 vaccination in Germany.
Allergol Select 7: 90-100.
Text
Berg P, Heiden M, Müller S, Oberle D, Funk M, Keller-Stanislawski B (2020): SARS-CoV-2-Infektionen und Sicherheit von Blut und Blutkomponenten.
Bulletin zur Arzneimittelsicherheit 11: 17-19.
Text
Börger V, Weiss DJ, Anderson JD, Borràs FE, Bussolati B, Carter DRF, Dominici M, Falcón-Pérez JM, Gimona M, Hill AF, Hoffman AM, de Kleijn D, Levine BL, Lim R, Lötvall J, Mitsialis A, Monguió-Tortajada M, Muraca M, Nieuwland R, Nowocin A, O'Driscoll L, Ortiz LA, Phinney DG, Reischl I, Rohde E, Sanzenbacher R, Théry C, Wei ST, Witwer KW, Lim SK, Giebel B (2020): ISEV and ISCT Statement on EVs From MSCs and Other Cells: Considerations for Potential Therapeutic Agents to Suppress COVID-19.
Cytotherapy 22: 482-485.
Online-Abstract
Cichutek K, Wagner R: Lessons Learned: die Zulassungsanforderungen für COVID-19-Impfstoffe.
In: Oberle D, Cichutek K, Wichmann O (Hrsg.), Impfen kompakt: fundierte Informationen aus dem Robert Koch-Institut und dem Paul-Ehrlich-Institut. 1. Aufl.: Urban & Fischer Verlag/Elsevier GmbH, 2024. 107-114 ISBN 978-3-437-23540-5
Corman VM, Rabenau HF, Adams O, Oberle D, Funk MB, Keller-Stanislawski B, Timm J, Drosten C, Ciesek S (2020): SARS-CoV-2 asymptomatic and symptomatic patients and risk for transfusion transmission.
Transfusion 60: 1119-1122.
Online-Abstract
Dewald F, Steger G, Fish I, Torre-Lage I, Hellriegel C, Milz E, Kolb-Bastigkeit A, Heger E, Fries M, Buess M, Marizy N, Michaelis B, Suárez I, Rubio Quintanares GH, Pirkl M, Aigner A, Oberste M, Hellmich M, Wong A, Orduz JC, Fätkenheuer G, Dötsch J, Kossow A, Moench EM, Quade Q, Neumann U, Kaiser R, Schranz M, Klein F (2024): SARS-CoV-2 Test-to-Stay in Daycare.
Pediatrics 153: e2023064668.
Text
Ebenig A, Lange MV, Gellhorn Serra M, Kupke A, Plesker R, Qu B, Brown RJP, Maier TJ, Mühlebach MD (2025): Differential efficacy of first licensed western vaccines protecting without immunopathogenesis Wuhan-1-challenged hamsters from severe COVID-19.
NPJ Vaccines 10: 51.
Text
Ebenig A, Muraleedharan S, Kazmierski J, Todt D, Auste A, Anzaghe M, Gömer A, Postmus D, Gogesch P, Niles M, Plesker R, Miskey C, Gellhorn Serra M, Breithaupt A, Hörner C, Kruip C, Ehmann R, Ivics Z, Waibler Z, Pfaender S, Wyler E, Landthaler M, Kupke A, Nouailles G, Goffinet C, Brown RJP, Mühlebach MD (2022): Vaccine-associated enhanced respiratory pathology in COVID-19 hamsters after TH2-biased immunization.
Cell Rep 40: 111214.
Online-Abstract
Glitscher M, Benz NI, Sabino C, Murra R, Hein S, Zahn T, Mhedhbi I, Stefanova D, Bender D, Werner S, Hildt E (2024): Inhibition of Pim kinases triggers a broad antiviral activity by affecting innate immunity and 2 via the PI3K-Akt-mTOR axis the endolysosomal system.
Antiviral Res 226: 105891.
Text
Görgülü E, Gu W, Trebicka J, Mücke VT, Mücke MM, Friedrich-Rust M, Bojunga J, Zeuzem S, Finkelmeier F, Peiffer KH (2022): Acute-on-chronic liver failure (ACLF) precipitated by severe alcoholic hepatitis: another collateral damage of the COVID-19 pandemic?.
Gut 71: 1036-1038.
Text
Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S (2021): Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination.
N Engl J Med 384: 2092-2101.
Text
Gürtler L, Seitz R, Schramm W (2021): Cerebral venous thrombosis after COVID-19 vaccination: is the risk of thrombosis increased by intravascular application of the vaccine?.
Infection 49: 1071–1074.
Text
Hastert FD, Hein S, von Rhein C, Benz NI, Husria Y, Oberle D, Maier TJ, Hildt E, Schnierle BS (2022): The SARS-CoV-2 Variant Omicron Is Able to Escape Vaccine-Induced Humoral Immune Responses, but Is Counteracted by Booster Vaccination.
Vaccines (Basel) 10: 794.
Text
Hastert FD, Henss L, von Rhein C, Gerbeth J, Wieters I, Borgans F, Khodamoradi Y, Zacharowski K, Rohde G, Vehreschild MJGT, Schnierle B (2022): Longitudinal Analysis of Coronavirus-Neutralizing Activity in COVID-19 Patients.
Viruses 14: 882.
Text
Hedberg P, Parczewski M, Serwin K, Marchetti G, Bai F, Jensen BEO, Pereira JPV, Drobniewski F, Reschreiter H, Naumovas D, Ceccherini-Silberstein F, Rubio Quintanares GH, Mwau M, Toscano C, König F, Pfeifer N, Zazzi M, Fanti I, Incardona F, Cozzi-Lepri A, Sönnerborg A, Nauclér P (2024): In-hospital mortality during the wild-type, alpha, delta, and omicron SARS-CoV-2 waves: a multinational cohort study in the EuCARE project.
Lancet Reg Health Eur 38: 100855.
Text
Hein S, Benz NI, Eisert J, Herrlein ML, Oberle D, Dreher M, Stingl JC, Hildt C, Hildt E (2021): Comirnaty-Elicited and Convalescent Sera Recognize Different Spike Epitopes.
Vaccines (Basel) 9: 1419.
Online-Abstract
Hein S, Herrlein ML, Mhedhbi I, Bender D, Haberger V, Benz N, Eisert J, Stingl J, Dreher M, Oberle D, Schulze J, Mache C, Budt M, Hildt C, Wolff T, Hildt E (2022): Analysis of BNT162b2- and CVnCoV-elicited sera and of convalescent sera towards SARS-CoV-2 viruses.
Allergy 77: 2080–2089.
Online-Abstract
Hein S, Mhedhbi I, Zahn T, Sabino C, Benz NI, Husria Y, Renelt PM, Braun F, Oberle D, Maier TJ, Hildt C, Hildt E (2022): Quantitative and Qualitative Difference in Antibody Response against Omicron and Ancestral SARS‐CoV‐2 after Third and Fourth Vaccination.
Vaccines (Basel) 10: 796.
Text
Hein S, Sabino C, Benz NI, Görgülü E, Maier TJ, Oberle D, Hildt E (2023): The fourth vaccination with a non-SARS-CoV-2 variant adapted vaccine fails to increase the breadth of the humoral immune response.
Sci Rep 13: 10820.
Text
Heinen N, Khanal R, Westhoven S, Klöhn M, Herrmann ST, Herrmann M, Tuoc T, Ulmke PA, Nguyen HD, Nguyen HP, Steinmann E, Todt D, Brown RJP, Sharma AD, Pfaender S (2024): Productive infection of primary human hepatocytes with SARS-CoV-2 induces antiviral and proinflammatory responses.
Gut 73: e14.
Text
Hennrich AA, Sawatsky B, Santos-Mandujano R, Banda DH, Oberhuber M, Schopf A, Pfaffinger V, Wittwer K, Riedel C, Pfaller CK, Conzelmann K (2021): Safe and effective two-in-one replicon-and-VLP minispike vaccine for COVID-19: Protection of mice after a single immunization.
PLoS Pathog 17: e1009064.
Online-Abstract
Henss L, Scholz T, von Rhein C, Wieters I, Borgans F, Eberhardt FJ, Zacharowski K, Ciesek S, Rohde G, Vehreschild M, Stephan C, Wolf T, Hofmann-Winkler H, Scheiblauer H, Schnierle BS (2020): Analysis of humoral immune responses in SARS-CoV-2 infected patients.
J Infect Dis 223: 56-61.
Online-Abstract
Henss L, Auste A, Schürmann C, Schmidt C, von Rhein C, Mühlebach MD, Schnierle BS (2021): The green tea catechin epigallocatechin gallate inhibits SARS-CoV-2 infection.
J Gen Virol 102: 001574.
Text
Herrlein ML, Hein S, Zahn T, Mhedhbi I, Raupach J, Husria Y, Benz NI, Eisert J, Bender D, Haberger V, Hastert FD, Henss L, Schnierle BS, Stingl JC, Dreher M, Hildt E (2022): Comparative Investigation of Methods for Analysis of SARS-CoV-2-Spike-Specific Antisera.
Viruses 14: 410.
Text
Hildt E (2022): Übersicht über die in der EU zugelassenen COVID-19-Impfstoffe – von der Technologie über die klinische Prüfung zur Zulassung.
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 65: 1237–1243.
Text
Hildt E, Schaade L (2022): Impfungen als Instrument der Pandemiebewältigung.
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 65: 1235-1236.
Text
Hörner C, Schürmann C, Auste A, Ebenig A, Muraleedharan S, Dinnon KH, Scholz T, Herrmann M, Schnierle B, Baric RS, Mühlebach MD (2020): A Highly Immunogenic Measles Virus-based Th1-biased COVID-19 Vaccine.
Proc Natl Acad Sci USA 117: 32657-32666.
Text
Jutel M, Torres MJ, Palomares O, Akdis CA, Eiwegger T, Untersmayr E, Barber D, Zemelka-Wiacek M, Kosowska A, Palmer E, Vieths S, Mahler V, Canonica GW, Nadeau K, Shamji MH, Agache I, EAACI Research and Outreach Committee Group (2022): COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals - EAACI recommendations.
Allergy 77: 2313-2336.
Text
Karamloo F, König R (2020): SARS-CoV-2 immunogenicity at the crossroads.
Allergy 75: 1822-1824.
Online-Abstract
Knezevic I, Mattiuzzo G, Page M, Nuebling CM, Griffiths E, Minor P (2022): Complexity of serological assays and misunderstandings of WHO International Units.
Clin Chem Lab Med 60: e223-e224.
Online-Abstract
Kochhar S, Excler JL, Kim D, Robertson JS, Fast PE, Condit RC, Drew S, Wood D, Gurwith M, Klug B, Whelan M, Khuri-Bulos N, Mallett Moore T, Smith ER, Chen RT, Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) (2020): The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines.
Vaccine 38: 6184-6189.
Online-Abstract
Kochhar S, Kim D, Excler JL, Condit RC, Robertson JS, Drew S, Whelan M, Wood D, Fast PE, Gurwith M, Klug B, Khuri-Bulos N, Smith ER, Chen RT, Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) (2020): The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines.
Vaccine 38: 5734-5739.
Text
Lasch F, Guizzaro L, Aguirre Dávila L, Müller-Vahl K, Koch A (2021): Potential impact of COVID-19 on ongoing clinical trials: a simulation study with the neurological Yale Global Tic Severity Scale based on the CANNA-TICS study.
Pharm Stat 20: 675-691.
Online-Abstract
HC Lehmann, Oberle D, Keller-Stanislawski B, Rieck T, Streit R (2023): Rare cases of Guillain-Barré syndrome after COVID-19 vaccination, Germany, December 2020 to August 2021.
Euro Surveill 28: 2200744.
Text
Liu M, Zhou T, Sheets R, Meyer H, Knezevic I (2022): WHO informal consultation on regulatory considerations for evaluation of the quality, safety and efficacy of RNA-based prophylactic vaccines for infectious diseases, 20-22 April 2021.
Emerg Microbes Infect 11: 384-391.
Online-Abstract
Lohse S, Sternjakob-Marthaler A, Lagemann P, Schöpe J, Rissland J, Seiwert N, Pfuhl T, Müllendorff A, Kiefer LS, Vogelgesang M, Vella L, Denk K, Vicari J, Zwick A, Lang I, Weber G, Geisel J, Rech J, Schnabel B, Hauptmann G, Holleczek B, Scheiblauer H, Wagenpfeil S, Smola S (2022): German federal-state-wide seroprevalence study of 1st SARS-CoV-2 pandemic wave shows importance of long-term antibody test performance.
Commun Med (Lond) 2: 52.
Text
Magari F, Messner H, Salisch F, Schmelzle SM, van Zandbergen G, Fürstner A, Ziebuhr J, Heine A, Müller-Ruttloff C, Grünweller A (2024): Potent anti-coronaviral activity of pateamines and new insights into their mode of action.
Heliyon 10: e33409.
Text
Mentzer D, Keller-Stanislawski B (2022): Verdachtsfälle von Nebenwirkungen und Impfkomplikationen nach Impfung mit Comirnaty® bei Kindern im Alter von 5–11 Jahren aus Deutschland: Meldungen an das Paul-Ehrlich-Institut bis zum 03.03.2022.
Bulletin zur Arzneimittelsicherheit 13: 15-21.
Text
Mentzer D, Keller-Stanislawski B (2022): Verdachtsfälle von Nebenwirkungen oder Impfkomplikationen nach Impfung mit den Omikron-adaptierten bivalenten COVID-19-Impfstoffen Comirnaty Original/Omicron BA.1, Comirnaty Original/Omicron BA.4-5, Spikevax bivalent/ Omicron BA.1 (bis 31.10.2022 in Deutschland gemeldet).
Bulletin zur Arzneimittelsicherheit 13: 29-34.
Text
Mentzer D, Oberle B, Streit R, Weisser K, Keller-Stanislawski B (2023): Sicherheitsprofil der COVID-19-Impfstoffe – Sachstand 31.03.2023.
Bulletin zur Arzneimittelsicherheit 14: 12-29.
Text
Meyer H (2021): COVID-19-Impfstoffe – Übersicht über in Europa zugelassene oder im Zulassungsprozess befindliche Impfstofftypen.
Bulletin zur Arzneimittelsicherheit 12: 20-22.
Text
Milne C, Wagner R, Cano F, Bruysters M, Waeterloos G, Pullirsch D, Wierer M, Mallet L (2023): Independent control of COVID-19 vaccines by EU Official Control Authority Batch Release: challenges, strengths and successes.
NPJ Vaccines Feb 23 [Epub ahead of print].
Text
Mönch K, Streit R, Keller-Stanislawski B (2022): Nuvaxovid® – gemeldete Verdachtsfälle von Nebenwirkungen in den ersten drei Monaten seit Beginn der Impfungen mit diesem Impfstoff.
Bulletin zur Arzneimittelsicherheit 13: 27-30.
Text
Müller-Olling M, Vahlensieck U, Hilger A (2021): Heterogeneity in COVID-19 Convalescent Plasma Clinical Trials.
Clin Pharmacol Ther 111: 995-1000.
Text
Niles MA, Gogesch P, Kronhart S, Ortega Iannazzo S, Kochs G, Waibler Z, Anzaghe M (2021): Macrophages and dendritic cells are not the major source of pro-inflammatory cytokines upon SARS-CoV-2 infection.
Front Immunol 12: 647824.
Online-Abstract
Oberle D, Mentzer D, Weber G (2020): Befragung zur Verträglichkeit der Impfstoffe gegen das neue Coronavirus (SARS-CoV-2) mittels Smartphone-App SafeVac 2.0.
Bulletin zur Arzneimittelsicherheit 11: 27-31.
Text
Peinemann F, Oberle D, Drechsel-Bäuerle U, Keller-Stanislawski B (2024): Adverse Menstrual Events Reported After and Before (or Without) COVID-19 Vaccination: A Systematic Review and Meta-Analysis of Comparative Observational Studies.
Pharmacoepidemiol Drug Saf 33: e5877.
Text
Pfaar O, Mahler V (2021): Allergic reactions to COVID-19 -vaccinations - unveiling the secret(s).
Allergy 76: 1621-1623.
Online-Abstract
Puyskens A, Krause E, Michel J, Nübling CM, Scheiblauer H, Bourquain D, Grossegesse M, Valusenko R, Corman VM, Drosten C, Zwirglmaier K, Wölfel R, Lange C, Kramer J, Friesen J, Ignatius R, Müller M, Schmidt-Chanasit J, Emmerich P, Schaade L, Nitsche A (2021): Establishment of a specimen panel for the decentralised technical evaluation of the sensitivity of 31 rapid diagnostic tests for SARS-CoV-2 antigen, Germany, September 2020 to April 2021.
Euro Surveill 26: 2100442.
Online-Abstract
Puyskens A, Bayram F, Sesver A, Michel J, Krause E, Bourquain D, Filomena A, Esser-Nobis K, Steffanowski C, Nübling CM, Scheiblauer H, Schaade L, Nitsche A (2023): Performance of 20 rapid antigen detection tests to detect SARS-CoV-2 B.1.617.2 (Delta) and B.1.1.529 (Omicron) variants using a clinical specimen panel from January 2022, Berlin, Germany.
Euro Surveill 28: 2200615.
Text
Qu B, Miskey C, Gömer A, Kleinert RDV, Calvo Ibanez S, Eberle R, Ebenig A, Postmus D, Nocke MK, Herrmann M, Itotia TK, Herrmann ST, Heinen N, Höck S, Hastert FD, von Rhein C, Schürmann C, Li X, van Zandbergen G, Widera M, Ciesek S, Schnierle BS, Tarr AW, Steinmann E, Goffinet C, Pfaender S, Krijnse Locker J, Mühlebach MD, Todt D, Brown RJP (2024): TMPRSS2-mediated SARS-CoV-2 uptake boosts innate immune activation, enhances cytopathology and drives convergent virus evolution.
Proc Natl Acad Sci U S A 121: e2407437121.
Text
Richter E, Al Arashi D, Schulte B, Bode C, Marx B, Aldabbagh S, Schlüter C, Kümmerer BM, Oldenburg J, Funk MB, Putensen C, Schmithausen RM, Hartmann G, Eis-Hübinger A, Streeck H (2021): Detectable SARS-CoV-2 RNAemia in Critically Ill Patients, but Not in Mild and Asymptomatic Infections.
Transfus Med Hemother 48: 154-159.
Text
Sampath V, Rabinowitz G, Shah M, Jain S, Diamant Z, Jesenak M, Rabin R, Jesenak M, Vieths S, Agache I, Akdis M, Barber D, Breiteneder H, Chinthrajah S, Chivato T, Collins W, Eiwegger T, Fast K, Fokkens W, O'Hehir RE, Ollert M, O'Mahony L, Palomares O, Pfaar O, Riggioni C, Shamji MH, Sokolowska M, Jose Torres M, Traidl-Hoffmann C, van Zelm M, Wang Y, Zhang L (2021): Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives.
Allergy 76: 1640-1660.
Text
Scheiblauer H, Filomena A, Nitsche A, Puyskens A, Corman VM, Drosten C, Zwirglmaier K, Lange C, Emmerich P, Müller M, Knauer O, Nübling CM (2021): Comparative sensitivity evaluation for 122 CE-marked rapid diagnostic tests for SARS-CoV-2 antigen, Germany, September 2020 to April 2021.
Euro Surveill 26: 2100441.
Text
Scheiblauer H, Nübling CM, Wolf T, Khodamoradi Y, Bellinghausen C, Sonntagbauer M, Esser-Nobis K, Filomena A, Mahler V, Maier TJ, Stephan C (2022): Antibody response to SARS-CoV-2 for more than one year − kinetics and persistence of detection are predominantly determined by avidity progression and test design.
J Clin Virol 146: 105052.
Text
Schramm W, Seitz R, Gürtler L (2020): COVID-19-associated coagulopathy - Hypothesis: Are Children protected due to enhanced thrombin inhibition by higher α2 -Macroglobulin (α2-M)?.
J Thromb Haemost 18: 2416-2418.
Online-Abstract
Sediri-Schön H, Lange J, Grabski E, Wagner R, Hildt E (2022): Chargenprüfung als wesentliche Säule der Versorgung mit sicheren und wirksamen Impfstoffen.
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 65: 1244-1250.
Text
Seitz R, Gürtler L, Schramm W (2024): COVID-19: A case for plasma derived natural anticoagulants?.
Biologicals 87: 101781.
Text
Seitz R, Gürtler L, Schramm W (2021): COVID-19 Convalescent Plasma: No Definite Answer Yet.
J Blood Lymph 11: 265.
Text
Seitz R, Gürtler L, Schramm W (2021): Thromboinflammation in COVID-19: Can α2-Macroglobulin Help to Control the Fire?.
J Thromb Haemost 19: 351-354.
Online-Abstract
Seitz R, Gürtler L, Vahlensieck U, Hilger A, Schramm W (2023): Too Early to Abandon Convalescent Plasma for Supportive Treatment of COVID-19.
Transufs Med Hemother 50: 1-3.
Text
Seitz R, Schramm W (2020): DIC in COVID-19: Implications for Prognosis and Treatment?.
J Thromb Haemost 18: 1798-1799.
Online-Abstract
Shivji R, Grabski E, Jekerle V (2024): Scientific and Regulatory Lessons Learnt on Building a Chemistry, Manufacturing, and Controls (CMC) Package for COVID-19 Variant Vaccine Updates in the EU - A Regulator’s Perspective.
Vaccines 12: 1234.
Text
Sokolowska M, Eiwegger T, Ollert M, Torres MJ, Barber D, Del Giacco S, Jutel M, Nadeau KC, Palomares O, Rabin RL, Riggioni C, Vieths S, Agache T, Shamji MH (2021): EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines.
Allergy 76: 1629-1639.
Online-Abstract
Srivastav S, Dankov A, Adanalic M, Grzeschik R, Tran V, Pagel-Wieder S, Gessler F, Spreitzer I, Scholz T, Schnierle B, Anastasiou OE, Dittmer U, Schlücker S (2021): Rapid and Sensitive SERS-Based Lateral Flow Test for SARS-CoV2-Specific IgM/IgG Antibodies.
Anal Chem 93: 12391-12399.
Online-Abstract
Stoliaroff-Pepin A, Peine C, Herath T, Lachmann J, Perriat D, Dörre A, Nitsche A, Michel J, Grossegesse M, Hofmann N, Rinner T, Kohl C, Brinkmann A, Meyer T, Dorner BG, Stern D, Treindl F, Hein S, Werel L, Hildt E, Gläser S, Schühlen H, Isner C, Peric A, Ghouzi A, Reichardt A, Janneck M, Lock G, Schaade L, Wichmann O, Harder T (2023): Effectiveness of vaccines in preventing hospitalization due to COVID-19: A multicenter hospital-based case-control study, Germany, June 2021 to January 2022.
Vaccine 41: 290-293.
Text
Theuerkauf SA, Michels A, Riechert V, Maier TJ, Flory E, Cichutek K, Buchholz CJ (2021): Quantitative Assays Reveal Cell Fusion at Minimal Levels of SARS-CoV-2 Spike Protein and Fusion-from-Without.
iScience 24: 102170.
Online-Abstract
Thiele T, Weisser K, Schönborn L, Funk MB, Weber G, Greinacher A, Keller-Stanislawski K (2022): Laboratory confirmed vaccine-induced immune thrombotic thrombocytopenia: Retrospective analysis of reported cases after vaccination with ChAdOx-1 nCoV-19 in Germany.
Lancet Reg Health Eur 12: 100270.
Online-Abstract
Timmesfeld N, Ihle P, Denz R, Meiszl K, Scholz K, Oberle D, Drechsel-Bäuerle U, Keller-Stanislawski B, Diebner HH, Meyer I (2024): Eine Machbarkeitsstudie zur Risikoevaluation der COVID-19-Impfstoffe (RiCO) auf Populationsebene in Deutschland – Nutzbarmachung verschiedener Sekundärdatenkörper für die Pharmakovigilanz und weitere Forschung.
Bulletin zur Arzneimittelsicherheit 15: 28-34.
Text
Turonova B, Sikora M, Schürmann C, Hagen WJH, Welsch S, Blanc FEC, Bülow von S, Gecht M, Bagola K, Hörner C, van Zandbergen G, Mosalaganti S, Schwarz A, Covino R, Mühlebach MD, Hummer G, Krijnse Locker J, Beck M (2020): In situ structural analysis of SARS-CoV-2 spike reveals flexibility mediated by three hinges.
Science 370: 203-208.
Text
von Rhein C, Scholz T, Henss L, Kronstein-Wiedemann R, Schwarz T, Rodionov RN, Corman VM, Tonn T, Schnierle BS (2021): Comparison of potency assays to assess SARS-CoV-2 neutralizing antibody capacity in COVID-19 convalescent plasma.
J Virol Methods 288: 114031.
Text
Wagner R, Hildt E, Grabski E, Sun Y, Meyer H, Lommel A, Keller-Stanislawski B, Müller-Berghaus J, Cichutek K (2021): Accelerated Development of COVID-19 Vaccines: Technology Platforms, Benefits, and Associated Risks.
Vaccines (Basel) 9: 747.
Text
Wagner R, Meißner J, Grabski E, Sun Y, Vieths S, Hildt E (2022): Regulatory concepts to guide and promote the accelerated but safe clinical development and licensure of COVID-19 vaccines in Europe.
Allergy 77: 72-82.
Online-Abstract
Weisser K, Kling K, Huth C, Keller-Stanislawski B, Mahler V (2021): Was ist bei positiver Allergieanamnese vor einer Impfung gegen COVID-19 zu beachten?.
Bulletin zur Arzneimittelsicherheit 12: 23-26.
Text
Zahn T, Mhedhbi I, Hein S, Raupach J, Miskey C, Husria Y, Bayanga K, Bartel D, Vieths S, Ivics Z, Oberle D, Keller-Stanislawski K, Herrlein ML, Maier TJ, Hildt E (2022): Persistence of infectious SARS-CoV-2 particles for up to 37 days in patients with mild COVID-19.
Allergy 77: 2053-2066.
Online-Abstract
